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ABSTRACT 
Background: A high prevalence of anemia was observed in HIV-infected individuals. Presence of auto-antibody 
also contributes for the development of anemia in HIV positive individuals. Few studies are conducted to show 
the prevalence of anemia in HIV positive individuals, but there is no documented data that rule out the 
prevalence of autoimmune hemolytic anemia (AIHA) in HIV positive individuals in Ethiopia. 
 
Objective: Determine the prevalence of autoimmune hemolytic anemia in HIV-infected adult patients at Tikur 
Anbessa Specialized teaching Hospital, Addis Ababa, Ethiopia. 
 
Methods: Hospital based cross sectional study was conducted on 384 HIV positive individuals using convenient 
sampling method from June 5, 2018 to September 10, 2019. Participants’ soco-demographic data, CD4 result 
and some important information was extracted from participants’ recorded data. Venous blood (5 ml) was 
collected for determination of HGB, RBC count, RBC indices, reticulocyte count and CBC results. After all, DAT 
was performed and blood film examination was done to confirm hemolysis. Finally data was analyzed using 
SPSS version 21 statistical soft ware package, and Descriptive statistic and Chi-square tests were used. 
 
Result: Of 384 study participants, 9 (2.34 %) patients are found to be AIHA positive. Of these, 6 (66.7 %) were 
females and 3 (33.3 %) were males. Nineteen patients had positive DAT result; 10 (52.6 %) had mild anemia, 4 
(21 %) moderate and 5 (26.3 %) severe anemia respectively. 37 (9.6 %) patients showed reticulocytopinea, 
while 31(8.1 %) patients had shown reticulocytosis. From 26 patients who showed evidence for the presence 
of hemolysis in their blood film, two individuals showed +2 graded hemolysis whereas 24 patients showed +1 
graded hemolysis. 
 
Conclusion: Prevalence of AIHA in HIV patients is not common. But it can be cause of anemia, most of the time 
in patients with severe-moderate ranged anemia and in patients with low CD4 count. 
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INTRODUCTION 
Anemia is the most common hematologic abnormality associated with HIV infection, 
affecting 60% to 80% of patients in late-stage disease [1]. Because of HIV virus or Anti 
retroviral treatment, the pathogenesis of anemia becomes more severe in these individuals 
than the normal one. This problem has great impact on economic and social well-being of 
HIV positive individuals; because it facilitates death, weakness and disease progression to 
Acquired Immunodeficiency Syndrome (AIDS) status [2, 3, 4]. Thus, it is very important to 
rule out and treat anemia in HIV patients appropriately.  
Warm auto antibodies to RBCs in AIHA are pathogenic and its etiology is unknown; In warm-
antibody AIHA, the auto antibodies that mediate RBC destruction are predominantly IgG 
globulins possessing relatively high binding affinity for human RBCs at 37°C. In addition to 
this, the auto antibodies of one patient often are specific for only a single RBC membrane 
protein; finally, these autoantibody-coated RBCs will be trapped by macrophages in the 
Billroth cords of the spleen and, to a lesser extent, by Kupffer cells in the liver and the 
process leads to generation of spherocytes, fragmentation and ingestion of antibody-coated 
RBCs [5].  
An inverse relationship between the quantity of RBC-bound IgG antibody and RBC survival is 
noted; as a result of this, it is very important to follow the DAT result of HIV patients even 
though, some findings say that the cases of Autoimmune Hemolytic Anemia occurred only in 
patients who are severely immune suppressed and also in the HAART era, when HIV-
infected people are treated more and more early, autoimmune diseases can occur, mainly 
at the phase of immunological recovery [5, 6]. 
In Ethiopia the prevalence of anemia in HIV/AIDS positive patients is estimated around 35%, 
this range from mild to moderate anemia [7, 8]. Findings showed that one-third of HAART 
naive HIV positive patients were anemic and the increase in prevalence of anemia with 
decreased CD4 cell count was statistically significant [7].  
Hemolytic anemia is any situation in which there is a reduction in RBC life-span due to RBC 
destruction by different internal or external factors. Auto immune hemolytic anemia is 
characterized by an increased breakdown of RBCs due to auto antibodies with or without 
complement activation [9, 5]. 
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Early diagnosis to identify the type of anemia for appropriate treatment in HIV patients is 
essential. However, few studies are conducted to show the prevalence of anemia in HIV 
positive individuals, but there is no documented data that characterize the prevalence of 
AIHA in HIV positive individuals in Ethiopia. Therefore, this study is planned to evaluate the 
prevalence of AIHA in HIV infected anemic adult patients attending Tikur Anbessa 
Specialized Teaching Hospital in Addis Ababa, Ethiopia. 
 
MATERIALS & METHODS 
Study Area 
The study was conducted in Tikur Anbessa specialized teaching Hospital, Addis Ababa, 
Ethiopia. It is one of the largest referral and teaching hospital of the country. In Hematology 
and immuno hematology laboratory perform 25 CBC testes per day for HIV sero positive 
individuals only. DAT test was conducted in national blood bank of Ethiopia.  
 
Study Design and Period 
Hospital based Cross sectional study was conducted in HIV positive patients at Tikur Anbessa 
Specialized Teaching Hospital, Addis Ababa, Ethiopia from July 5, 2018 to September 10, 
2019.  
 
Source population 
HIV positive individuals who were sent to laboratory of Tikur Anbessa Specialized Teaching 
Hospital during the study period were the source population. 
 
Study population 
HIV positive individuals who came to hematology unit, who developed anemia, met the 
inclusion criteria and volunteered patients were the study population. 
 
Sample size and Sampling Technique 
The required sample size for this study was calculated using single population proportion 
formula and finally 384 participants were recruited using convenient sampling technique. 
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Inclusion Criteria 
HIV positive patients who were not transfused in previous three months, those who were 
volunteers and who develop anemia were included. 
 
Exclusion Criteria 
Participant whose age is below 14, individuals who came to the laboratory more than once 
during the study period and hemolysed and inappropriate proportion with EDTA samples 
were excluded from the study. 
 
Data collection procedure 
Participants’ soco-demographic data and CD4 result were extracted from Participants’ 
records, from patient card and request paper. About 5ml of venous blood was drawn from 
each participant into sodium ethylene diamine tetra-acetate (EDTA) test tube. This sample 
was used to measure full blood count using automatic hematology analyzer (Sysmex 
XT2000i Analyzer, made by Sysmex Coorporation Kobe, Japan), RBC count and RBC indices. 
For reticulocyte count manual method was used; finally, blood film examination was 
performed using collected blood and DAT was analyzed. In blood film we were looking for 
the presence of schistocytes, spherosyt, nucleated RBC and in the mean time we cross 
cheek for morphology with analyzer result. Finally, reticulocyt count was performed using 
Brilliant Crestal Blue by incubating 3 drop of blood with 3 drop of reagent for  25-30 minute, 
after all smear prepared and retics count was performed. 
 
Data analysis and result interpretation 
Data entry and analysis were done by using SPSS statistical software version 21. Descriptive 
statistics; for CD4, retics, severe to moderate ranged anemia, and x2 (for CD4 and retics, 
evidence for presence of hemolysis and CD4) test were used. The results were presented in 
words, percentages, graphs and tables. Based on the study result, conclusions and 
recommendations were made. 
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Data quality control 
Pre-analytical: To assure the quality of the data, training was given to the data collectors to 
minimize technical and observer bias. Standard operating procedures were strictly followed 
during specimen collection and laboratory procedures. 
Analytical: Quality control for working equipments and reagents was ensured using standard 
controls as well as standard operational procedures were implemented and Sysmex normal 
back ground reading was also included daily. The result of each and every test was properly 
recorded. The same procedure, for DAT, was repeated with Coomb's positive and negative 
cells as control for each batch. Microscopic smear review was performed to check RBC 
morphology and to see distribution if there is doubt in result or for extremely outranged 
result. As a quality control for retics count, 500 cells was counted on two slides each and 
result should agree within range of ± 15% each other. If they do not, reticulocyte count was 
repeated on the third smear. 
Post analytical: Every day, the collected data was checked for completeness and accuracy by 
the principal investigator. During the entry of data it was cross checked to assure the right 
data was entered correctly. 
 
Ethical Consideration 
Ethical approval was obtained from Research Ethical Review Committee of Addis Ababa 
University. Permission was also obtained from Tikur Anbessa Specialized Hospital medical 
director, ART department head and laboratory head, document and record officer and also 
from national blood bank administrator and laboratory head. All the information obtained 
from the study participants were coded to maintain confidentiality and data were collected 
after written informed consent was obtained. Full explanation about the purpose of the 
study was made to persons who full fill the inclusion criteria and expected to participate in 
the study. These candidates were informed of their right to refuse or agree to be part of the 
study, or terminate their participation. 
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Operational Definitions 
HGB: below 12.8 and 13.8 g/dl for females and male respectively is considered as anemia 
and classification of anemia was be based on WHO criteria.  
DAT positive: from +1 to +4 agglutination of washed RBC with Anti-human globulin reagent. 
Reticulocytosis: reticulocyte count greater than 1.8%.  
Reticulocytopenia:  reticulocyte count less than 0.4%.  
Anemic: hemoglobin value less than 12.8 g/dl for female and less than 13.8g/dl for male. 
AIHA positive: First, the anemia has to be normocytic normochromic anemia (MCV= 90 ± 
10; MCH= 27-32), second there has to be evidence for the presence of hemolysis in blood 
film such as:-spherosytosis or schistocytes (Helement cell, Karatocyte (horned cell) 
Triangular cell), nucleated RBC; third, DAT has to positive and a reticulocyte count must be 
greater than 1.8%. The presence of erythrophagocytosis by monocyte may be seen in severe 
cases and agglutinated RBC may be seen uncommonly in warm AIHA. These findings in 
blood film, with other parameters, used as evidence for the presence of AIHA. 
Blood film finding interpretation: - The presence of <1% fragments in the PBF is considered 
normal and 1-5, 6–14 and>15% finding of fragmented cell in blood film is reported as +1, +2 
and +3 respectively. However, the finding of even a single spherocyte and nucleated RBC is 
considered as indicators since, they are usually absent in the blood films of healthy 
individuals. Reporting and interpretation was as follows, 1-5, 6–19, >20% finding of 
spherocyte in blood film was reported as +1, +2 and +3 respectively. 
 
RESULT 
Demographic Characterstics  
Among 384 participants, 100 (26.1%) were males and 284 (73.9%) were females. All female 
participants were non- pregnant during the study time. The mean age of the study 
participant were 36 +/- with SD of 12 years and 116 (30.2 %) were in the age group of 36 - 
42 years (Table 1). From all participants, 9 (2.34 %) were found to be AIHA positive, 6 (66.7 
%) females and 3 (33.3 %) males respectively, and only 10 other patients had positive DAT 
without being AIHA positive. 
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Table 1: The demographic characteristic of the study population at Tikur 
Anbessa Specialized Teaching Hospital; Addis Ababa, Ethiopia, from June 5, 2018 
to September 10, 2019. 
Age(year) Male (%) Female( % ) Total (%) 
15-21 23 (6.0) 31(8.1) 54 (14.1) 
22-28 11 (2.9) 34(8.9) 45 (11.7) 
29-35 10 (2.6) 68(17.7) 78 (20.3) 
36-42 22 (5.7) 94(24.5) 116 (30.2) 
43-49 12 (3.1) 17(4.4) 29 (7.5) 
50-56 14 (3.6) 31(8.1) 45 (11.7) 
57-63 4 (1.0) 4(1.0) 8 (2.0) 
64-70 2 (0.5) 5 (1.3) 7 (1.8) 
71-77 2 (0.5) 0 (0) 2 (0.5) 
Total 100 
(26.1) 
284 
(73.9) 
384 (100) 
 
CD4 distribution and hemolysis at different anemia stage  
Hemoglobin of the study participants was ranged from 5.00 to 13.7 g/dl. From 25 patients 
who had severe anemia, 18 (72 %) females and 7 (28 %) males, 16 (64 %) of them had CD4 
count below 200 cell per cubic mm whereas the remaining had CD4 count above 200. From 
severe anemia developed patients 3 (12 %) had evidence for hemolysis in their blood film 
while 6 (8.2 %) and 17 (6 %) patients also had blood film finding for hemolysis with 
moderate and mild anemia respectively. The most prevalent type of anemia was 
normocytic normochromic anemia which accounted for 216 (56.25 %) and followed by 
macrocytic normochromic anemia, 107 (27.9 %), and microcytic hypochromic, 22 (5.73 %), 
respectively. The severity of anemia in study participant is displayed in Table 2. 
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Type of Anemea  Number (Percent) 
Severe Anemia 25 (6.51%) 
Moderate Anemia 73 (19.01%) 
Mild Anemia 286 (74.48%) 
Total 384 (100%) 
 
DAT result at different anemia level and hemolysis   
Highly frequent AIHA positive patients, 3 (33.3 %) were seen in age group 43-49 followed 
by 50-56 and 29-35 age group with 2 (22.2 %) AIHA positive patient each and lastly in age 
group 22-28 and 36-42 with one patients each. From 9 patients who develop AIHA, 8 (89 %) 
of them were on HARRT and 1 (11 %) was naive for HAART. From 9 patients who developed 
AIHA, 2 (22.2 %) patients had shown severe anemia, 3 (33.3 %) of them moderate and 4 
(44.4%) mild anemia respectively and also 6 (66.7 %) patients had CD4 count less than 200 
cell/cubic mm and 3 (33.3 %) of the them had CD4 count greater than 201 cell/cubic mm. 
There were only 2 (0.52 %) patients who were AIHA positive without having increased 
reticulocyte count and there was no patient whose DAT was negative and AIHA positive. 
Nineteen (4.9 %) patients had positive DAT result; 10 (52.6 %) had mild anemia, 4 (21 %) 
moderate and 5 (26.3%) severe anemia respectively. And from those whose DAT was 
positive, 14 (73.6 %) patients had a finding for presence of hemolysis in blood film 
and only 5 (26.31 %) patients had positive DAT result without the presence of evidence 
for hemolysis in their blood film. Twelve patients were negative for DAT result but showed 
evidence for hemolysis in their blood film finding (Table 2). 
Table 2:- CD4 count, DAT result and HAART usage of the study participants at Tikur 
Anbessa Specialized Teaching Hospital; Addis Ababa, Ethiopia, from June 5, 2018 to 
September 10, 2019. 
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Variable  CD4 DAT HAART 
<200 >201 Positive  Negative  Naive  User 
Age 
   15-21 
   22-28 
   29-35 
   36-42 
   43-49 
   50-56 
   57-63 
   64-70 
   71-77 
 
6 
11 
25 
22 
8 
6 
1 
0 
1 
 
48 
34 
53 
94 
21 
39 
7 
7 
1 
 
0 
4 
4 
3 
3 
4 
0 
1 
0 
 
54 
41 
74 
113 
26 
41 
8 
6 
2 
 
0 
1 
2 
1 
3 
2 
0 
0 
0 
 
54 
44 
76 
115 
26 
43 
8 
7 
2 
Sex 
    Male  
    Female 
 
22 
58 
 
78 
226 
 
4 
15 
 
96 
269 
 
3 
6 
 
97 
278 
 
Reticulocyte count at different anemia level and their DAT result  
The mean of reticulocyte count was 0.93 with 0.67 SD. The distribution frequency 
for reticulocyte count is shown in fig 2. From 31 patients whose reticulocyte count was 
greater than 1.82, 4 (12.9 %) patients had severe while 7 (22.6 %) and 21(67.7 %) patients 
had moderate and mild anemia respectively. On the other hand, from this 31 previously 
mentioned patients 19 (61.3 %) of them were negative for DAT while only 12 (38.7 %) 
patients were positive for DAT test. Reticulocytosis was more common in females, 20 
(64.5 %), than in males. Chi-square test was performed to see the association for 
severity of anemia with reticulocyte count of the patients, and no statistically significant 
association was found between severe and moderate type of anemia with reticulocyte 
count , x
2
 (1, N= 384)= 1.76 , p= 0.184. 
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From 26 patients who showed evidence for the presence hemolysis in their blood film, two 
individuals showed that +2 graded hemolysis, whereas 24 patients showed +1 graded 
hemolysis, 8 (30.8 %) individuals had CD4 count below 200 cell per cubic millimeter while 18 
(69.2 %) patients had CD4 count above 201. And from those 26 hemolysis developed 
patients 12 (46.1 %) had reticulocyte count above 1.82 whereas 14 (53.8 %) patients had 
reticulocyte count below 1.82. Chi-square test was performed and no statistically significant 
association had been found between CD4 count and the presence of evidence for hemolysis 
in blood film in, x
2
 (1, N= 384) = 1.67, p= 1. 
 
Figure 2: Histogram showing frequency of reticulocyte count of the study population at 
TASH, Addis Ababa, Ethiopia, from June 5, 2018 to September 10, 2019. 
 
Reticulocyte count at different CD4 count  
Thirty seven (9.6 %) patients showed reticulo cytopenia while 31(8.1 %) patients had shown 
reticulocytosis. CD4 result of the study participants showed that 80 (20.8 %) patients had 
CD4 count below 200, of them 9 patients were positive for DAT, and 304 had CD4 count 
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above 201. From 31(8.1 %) patients whose reticulocyte count was above 1.82:- 12 (38.7 %) 
patients had CD4 count below 200, 3 (9.67 %) from 201-350 and 7 (22.6 %) from 351-500 
respectively. Chi-square test was performed to see the relationship between reticulocyte 
count and the CD4 result of the patient, and statistically significant association was found 
between  reticulocyte count and CD4 result , x
2
 (1, N= 384)= 6.53 , p= 0.01; RR= 2.4.  
 
Figure 3: Box plot showing CD4 distribution of the study participant at TASH, Addis Ababa, 
Ethiopia, from June 5, 2018 to September 10, 2019. 
 
DISCUSSION  
This study showed, noromcytic normochromic anemia is 56.25 %, this findig agreed with the 
study conducted in Mexico in which 85 % of their participants were noromcytic 
normochromic anemia [10]. This also agrees with the study conducted in Ethiopia on 
determination of immunological and hematological parameters among HIV positive patients 
taking HAART and treatment naive in ART clinic of Gonder university and they found that 
the prevalence of normocytic normochromic was 43.3 % and they concluded that it is the 
dominate type of anemia in their patients [11].   
The prevalence of AIHA on this study was 2.34 %; and it is consistent with study done by 
Volberding PA et al; in which they confirmed that AIHA is not common in HIV patients [12]. 
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This value also agrees with previous study conducted in Nigeria where AIHA was rare with 
the prevalence of 3.06 % [13], and also it is comparable with the study conducted by 
Adewumi AA et al and they found that from the total of 350 HIV infected participants none 
of them (0%) were found to be AIHA positive patients [14]. According to Salawn L et al study 
autoimmune disorders are rare in indigenous African population and they assumed that this 
may be because of the widespread infectious diseases which impaired host T-cell immunity 
[15]. Other study conducted by Telen MJ et al suggested that the frequent lack of 
reticulocytosis may lead to under diagnosis of the disease in these populations [16]. 
In this study most of AIHA developed participants were female, 6 (66.7 %), which agrees 
with study done in Denmark in which they deduced that most autoimmune disease are 
more common in females [17].  
From all AIHA developed participants, 5 (55.5 %) of them were above 40 years, and this is 
similar to Gunawardena D et al finding in which they state that AIHA can occur at any age 
stage but mostly AIHA is found in individuals whose age are above 40 [18]. 
From all AIHA developed participants, 2 (22.2 %) of them had severe and 3 (33.3 %) of them 
had moderate anemia respectively. This is comparable with Salawn L et al study in which 
they found that all AIHA positive patients had severe-moderate anemia [15]. It is also in 
agreement with Kamesaki T et al, in which the hemoglobin level was significantly low in 
patients with AIHA [19].  
From all AIHA developed participants, 6 (66.7 %) had CD4 count less than 200 cell/cubic mm. 
This finding seems to agree, not perfectly, with Iordache L et al finding where all of 
autoimmune hemolytic anemia occurred only in patients with severely immuno-depressed 
[6]. But our finding completely disagrees with Shoenfeld Y et al finding in which they 
proposed that autoimmune diseases occur when there is no immunosuppression such as 
during acute infection (Stage I), when the CD4 count > 200 (Stage II) or following highly 
active antiretroviral therapy (Stage IV). According to their finding autoimmune disease is not 
reported in patients with profound immunosuppression (Stage III) [20]. This significant 
variation may be because they include many autoimmune diseases in addition to AIHA.  
Based on this finding only 2 (22.2 %) patients had severe anemia with AIHA development. 
This result is lower than Koduri PR et al finding where all AIHA patients infected with HIV-1 
had severe anemia and even they required blood transfusion [21]. This variation may be due 
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to; some of their patients were bleeding due to Disseminated Intravascular Coagulation 
(DIC) and may also have obscured cause of anemia.  
In this study, the severity of anemia was related with CD4 count and non-perfectly with DAT 
positivity of patients. From a total of 25 severe anemia developed patients, 16 (64%) of 
them had CD4 count below 200 cell/ cubic mm and from a total of 19 DAT positive 
individuals 9 (47.4 %) of them had severe-moderate ranged anemia. This finding is 
consistent with study done by Ferede G et al, in which they showed that increase in 
prevalence of anemia with decreased CD4 cell count was statistically significant [7] and 
agree, not perfectly, with study done by Lai M et al, which states that anemia was related 
with the DAT results [22]. The reason for this non perfect agreement may be due to the 
HAART drug and life style effect on hemoglobin count of economically varied countries.   
Based on this study finding among 19 patients whose DAT was positive 12 (63.2 %) of them 
had CD4 count below 350. This find is similar with Volberding PA et al declaration in which 
they state that the prevalence of DAT positivity increased with more advanced stage of HIV 
infection [12] and also consistent with Angelis VD et al finding, in which they found that DAT 
positivity worsen the clinical conditions of HIV patients [23].  
Nineteen (4.9 %) patients in this study had positive DAT. This is highly lower than Angelis VD 
et al finding in which they found that DAT positivity is shown in 34 % of their participants 
[23]. It was slightly lower than Nigerian’s studies in which they found that 11.22 % of their 
participant was positive for DAT [13] but it is higher than Adewumi A et al in which they 
found that only 2 out of 350 (0.6 %) patients were positive for DAT [14]. Rheingold SR et al 
stated that DAT positivity in HIV infected patient’s ranges from 34% to 85% [24]. 
From 19 DAT positive patients only 14 (73.7 %) of them showed evidence of hemolysis in 
their blood film where as 5 (26.3 %) patients have positive DAT without hemolysis this may 
be because some compliments (like C3) don’t seem to have any hemolysis even if DAT is 
positive [23] and positive DAT not in all cases associated with an overt hemolytic anemia 
[26]; In addition, drug-related nonimmunologic protein adsorption by RBCs may result in a 
positive DAT without actual RBC injury [5].  
Statistically significant association had been found between reticulocyte count and CD4 
count of the study participants. This significant association is due to cytopenia is more 
common in HIV positive patients [27]. Based on this study, 37 (9.6 %) patients had shown 
reticulocytopenia and this finding is not consistent with study done by Volberding PA et al in 
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which they stated that reticulocytopenia is sufficiently frequent in those with HIV infection 
[19]. According to Thedsawad A et al finding this variation may be due to the course of 
infection influence on reticulocyte count that reticulocyte count may not be elevated early 
in the course of the infection of the disease [28].  
In this study from a total of 26 patients who showed evidence for presence of hemolysis in 
their blood film, only 8 (30.8%) patients had CD4 count below 200 cell per cubic millimeter 
and no statistically significant association was found between the presence of evidence for 
hemolysis in blood film and CD4 count. It is in contrast with Koduri PR et al finding, in which 
all their participant had CD4 count below 200 [21]. This variation is due to extra vascular 
hemolysis predominate intravascular hemolysis.  
 
CONCLUSION  
Based on the findings of this study, AIHA in HIV positive anemic patients is rare with the 
prevalence of 2.34%. AIHA occur mostly in advanced age stage and among female. 
Autoimmune hemolytic anemia consideration will be important if patients experience 
severe-moderate ranged anemia and in patients with low CD4 count. This study would 
encourage ART clinicians and others to know the current burden of AIHA in HIV patients and 
help ART clinicians and laboratory personnel to suspect and investigate AIHA, as the possible 
etiology of anemia in HIV positive patients.  
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